LitAlert ~~ GeneLit.com

    • Diagnostic, Predictive and Prognostic Molecular Biomarkers in Pancreatic Cancer: An Overview for Clinicians.
    • Giannis D, Moris D, Barbas AS.
    • Cancers (Basel). 2021 Mar 3;13(5):E1071. doi: 10.3390/cancers13051071.

    • The BRCA1 c.788G > T (NM_007294.4) variant in a high grade serous ovarian cancer (HGSOC) patient: foods for thought.
    • De Paolis E, Pietragalla A, De Bonis M, Fagotti A, Urbani A, Scambia G, Minucci A.
    • Mol Biol Rep. 2021 Mar 3. doi: 10.1007/s11033-021-06243-x. Epub ahead of print.
    • Case report

    • Myriad Genetics, Intermountain Healthcare Collaborate for Cancer Testing Service.
    • [No author given]
    • GenomeWeb. Business & Policy. Business News. 2021 Mar 2.

    • Molecular characterization of high-grade serous ovarian cancers occurring in younger and older women.
    • Filippova OT, Selenica P, Pareja F, Vahdatinia M, Zhu Y, Pei X, Riaz N, Long Roche K, Chi DS, Abu-Rustum NR, Ellenson LH, Reis-Filho JS, Zamarin D.
    • Gynecol Oncol. 2021 Mar 2:S0090-8258(21)00173-6. doi: 10.1016/j.ygyno.2021.02.028. Epub ahead of print.

    • Perspectives on PARP inhibitors as pharmacotherapeutic strategies for breast cancer.
    • Oh SY, Rahman S, Sparano JA.
    • Expert Opin Pharmacother. 2021 Mar 1. doi: 10.1080/14656566.2021.1876662. Epub ahead of print.
    • Review

    • Blocking Fra-1 sensitizes triple-negative breast cancer to PARP inhibitor.
    • Song D, He H, Sinha I, Hases L, Yan F, Archer A, Haldosen LA, Zhao C, Williams C.
    • Cancer Lett. 2021 Feb 27:S0304-3835(21)00092-6. doi: 10.1016/j.canlet.2021.02.018. Epub ahead of print.

    • Loss of BRCA1 expression and morphological features associated with BRCA1 promoter methylation status in triple-negative breast cancer.
    • Morizono A, Tanabe M, Ikemura M, Sasaki T, Ushiku T, Seto Y.
    • J Hum Genet. 2021 Feb 27. doi: 10.1038/s10038-021-00911-3. Epub ahead of print.

    • Nouvelles AMMs : niraparib et olaparib en première ligne dans les cancers de l’ovaire [New drug approval: Olaparib and niraparib - first line in ovarian cancer].
    • Delaye M, Rodrigues M.
    • Bull Cancer. 2021 Feb 25:S0007-4551(21)00038-2. French. doi: 10.1016/j.bulcan.2021.01.003. Epub ahead of print.
    • Letter, [Article in French]

    • Synchronous breast carcinoma and peritoneal mesothelioma.
    • Prathibha S, Beckwith H, Kratzke RA, Klein M, Kne A, Tuttle TM.
    • Breast J. 2021 Feb 23. doi: 10.1111/tbj.14202. Epub ahead of print.
    • Case report

    • Therapeutic Potential of Olaparib in Combination With Pembrolizumab in a Young Patient With a Maternally Inherited BRCA2 Germline Variant: A Research Report.
    • Waddington T, Mambetsariev I, Pharaon R, Fricke J, Baroz AR, Romo H, Ghanem B, Gray S, Salgia R.
    • Clin Lung Cancer. 2021 Jan 27:S1525-7304(21)00012-7. doi: 10.1016/j.cllc.2021.01.009. Epub ahead of print.
    • Case report